- Home
- IPHA vs CRVS Comparison
IPHA vs CRVS Comparison
Compare IPHA & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- CRVS
- Stock Information
- Founded
- IPHA 1999
- CRVS 2014
- Country
- IPHA France
- CRVS United States
- Employees
- IPHA N/A
- CRVS N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- IPHA Health Care
- CRVS Health Care
- Exchange
- IPHA Nasdaq
- CRVS Nasdaq
- Market Cap
- IPHA 148.3M
- CRVS 516.0M
- IPO Year
- IPHA 2019
- CRVS 2016
- Fundamental
- Price
- IPHA $1.79
- CRVS $5.10
- Analyst Decision
- IPHA Strong Buy
- CRVS Strong Buy
- Analyst Count
- IPHA 1
- CRVS 5
- Target Price
- IPHA $11.50
- CRVS $12.38
- AVG Volume (30 Days)
- IPHA 779.8K
- CRVS 1.7M
- Earning Date
- IPHA 09-12-2024
- CRVS 11-12-2024
- Dividend Yield
- IPHA N/A
- CRVS N/A
- EPS Growth
- IPHA N/A
- CRVS N/A
- EPS
- IPHA N/A
- CRVS N/A
- Revenue
- IPHA $36,202,722.00
- CRVS N/A
- Revenue This Year
- IPHA N/A
- CRVS N/A
- Revenue Next Year
- IPHA $101.65
- CRVS N/A
- P/E Ratio
- IPHA N/A
- CRVS N/A
- Revenue Growth
- IPHA N/A
- CRVS N/A
- 52 Week Low
- IPHA $1.29
- CRVS $1.30
- 52 Week High
- IPHA $3.51
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- IPHA 45.92
- CRVS 36.16
- Support Level
- IPHA $1.64
- CRVS $4.93
- Resistance Level
- IPHA $1.87
- CRVS $6.47
- Average True Range (ATR)
- IPHA 0.12
- CRVS 0.40
- MACD
- IPHA -0.04
- CRVS 0.06
- Stochastic Oscillator
- IPHA 28.66
- CRVS 29.74
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).